2026 PBC Patient Survey Results
The Canadian PBC Society is committed to advocating for people living with PBC. In the spring of 2026, 324 people living with PBC from across Canada shared their experiences by
LYVDELZI® approved for PBC by Health Canada
Gilead Science Inc announced that Health Canada has approved LYVDELZI® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have hadIpsen’s Iqirvo® receives Health Canada approval as a first-in-class PPAR treatment for primary biliary cholangitis
April 28, 2025 – Ipsen Biopharmaceuticals Canada Inc. today announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving IQIRVO® (elafibranor) for the treatment of primary biliary cholangitisObeticholic Acid in Europe, USA and Canada
FOR RELEASE ON JULY 5, 2024 7:00 AM EST – NEW YORK / TORONTO PBCers and Canadian PBC Society Press Release for PBC Patients: Important Information for PBC Patients Regarding
CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar
The 52-week IDEAL study aims to enroll 75 patients with PBC who have an incomplete response or intolerance to ursodeoxycholic acid (UDCA), in each case with ALP greater than the
Ipsen and GENFIT announce positive Phase 3 trial data
Ipsen and GENFIT announce positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual α,δ PPAR agonist, is
Fixed dose combination OCA/Bezafibrate positive interim Phase 2 study results.
Intercept Pharmaceuticals announces new data showing potential of Fixed-Dose Combination of OCA and Bezafibrate to normalize multiple biomarkers in PBC to be featured in podium presentation at EASL Congress June
Linerixibat GLISTEN phase 3 study now enrolling
The GLISTEN clinical trial is investigating a potential new treatment specifically for PBC itch and is now enrolling patients worldwide. In Canada, the study is currently enrolling in Toronto, Ontario. Fixed-dose combination OCA/Bezafibrate granted orphan drug designation by FDA
Intercept Pharmaceuticals is investigating a fixed-dose combination of OCA and bezafibrate for the potential treatment of individuals with PBC. Clinical trials are underway to establish safety and efficacy. OCA, a